Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sclerotherapy for hydroceles.

R K Rencken1, M S Bornman, S Reif

  • 1Department of Urology, Medical University of Southern Africa, Pretoria.

The Journal of Urology
|May 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The prognostic relevance of full-thickness burns on ABSI.

Burns : journal of the International Society for Burn Injuries·2024
Same author

Supporting patients with heart failure with digital therapeutics-A pilot study in Germany.

Digital health·2022
Same author

EDCs and male urogenital cancers.

Advances in pharmacology (San Diego, Calif.)·2021
Same author

Depressive symptoms, impaired glucose metabolism, high visceral fat, and high systolic blood pressure in a subgroup of women with recent gestational diabetes.

Journal of psychiatric research·2017
Same author

Physical fitness and plasma leptin in women with recent gestational diabetes.

PloS one·2017
Same author

First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same journal

On the Memoryless Property in Markov Models for NMIBC Cost-Effectiveness Analysis.

The Journal of urology·2026
Same journal

Multi-institutional Assessment of Performance Metrics for MRI-targeted Transperineal Prostate Biopsy.

The Journal of urology·2026
Same journal

Urinary Supersaturation in a Randomized Trial among Individuals with Recurrent Nephrolithiasis comparing Empiric versus Selective Preventive Therapy: The URINE Trial.

The Journal of urology·2026
Same journal

The FDA Should Allow More BCG Strains into the US Market: How Recent Landmark Trials Expose a Regulatory Paradox.

The Journal of urology·2026
Same journal

Let's Shift the Focus from Death to Life after Fournier's Gangrene.

The Journal of urology·2026
Same journal

Endourology and Nephrolithiasis.

The Journal of urology·2026
See all related articles

Sclerotherapy using sodium tetradecyl sulfate and rolitetracycline effectively treated 55 hydroceles with a 96% cure rate. This outpatient procedure offers an economical and safe solution for hydrocele management.

Area of Science:

  • Urology
  • Surgical Innovation
  • Outpatient Procedures

Background:

  • Hydroceles are common scrotal swellings.
  • Surgical excision has traditionally been the primary treatment.
  • Minimally invasive options are sought for improved patient outcomes.

Purpose of the Study:

  • To evaluate the efficacy and safety of sclerotherapy for hydroceles.
  • To assess the cure rate and complication profile of this outpatient treatment.
  • To determine the economic viability of sclerotherapy as a hydrocele therapy.

Main Methods:

  • 55 patients with hydroceles underwent outpatient sclerotherapy.
  • The sclerosant agents used were 3% sodium tetradecyl sulfate and 3.5% rolitetracycline.
  • Follow-up averaged 13 months to assess outcomes.

Related Experiment Videos

Main Results:

  • An overall cure rate of 96% was achieved.
  • 64% of patients were cured after a single sclerosing instillation.
  • Significant pain occurred in only 29% of patients, with a 4% need for post-sclerotherapy surgery.

Conclusions:

  • Sclerotherapy is a highly effective treatment for hydroceles.
  • The procedure demonstrates favorable safety, economic, and efficacy profiles for outpatient management.
  • Sclerotherapy represents a viable, less invasive alternative to surgery for hydroceles.